drugset / Trial / NCT02237547

Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury

NCT02237547

Phase 1/2 Withdrawn Translational Biosciences
NaSingle-groupOpen-labelTreatment

Summary

Human Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) and Bone Marrow Mononuclear Cells (BMMC) from the patient injected into the spinal fluid intrathecally and injected intravenously (IV) is a safe and therapeutic procedure for spinal cord injury (SCI) patients.

Timeline

Start
2014-09
Primary completion
2019-01
Completion
2019-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Human umbilical cord tissue-derived mesenchymal stem cells Cell therapy Intrathecal
Subject bone marrow mononuclear cells Cell therapy Intrathecal

Indications